AstraZeneca to acquire Alexion for $39B

Samstag, 12. Dezember 2020 14:32

AstraZeneca PLC announced on Saturday it will acquire Alexion Pharmaceuticals Inc. for a price of $39 billion.

Current Alexion shareholders will be entitled to $60 in cash and 2.1243 AstraZeneca ADR per tendered share "based on AstraZeneca's reference average American Depositary Receipts (ADR) price of $54.14, this implies total consideration to Alexion shareholders of $39 billion or $175 per share."

According to the official statement, "the boards of directors of both companies have unanimously approved the acquisition. Subject to receipt of regulatory clearances and approval by shareholders of both companies, the acquisition is expected to close in the third quarter of 2021, and upon completion, Alexion shareholders will own approximately 15% of the combined company."

Slični linkovi: AstraZeneca plcAlexion Pharmaceuticals Inc.
Autor:
Breaking the News / CG